Table 2 Hazard ratios of COVID-19 (A) per 10-fold increase or (B) per standard deviation increase in each D57 marker in baseline negative vaccine recipients.

From: Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine

A

D57 Antibody Marker

Hazard Ratio per 10-fold Increase

P-value* (2-sided)

Q-value**

FWER**

Point Est.

95% CI

Anti Spike IgG (BAU/ml)

0.32

(0.14, 0.76)

0.009

0.017

0.015

PsV-nAb ID50 (IU50/ml)

0.28

(0.10, 0.77)

0.013

0.019

0.016

B

D57 Antibody Marker

Hazard Ratio per Standard Deviation-Increment Increase

   

Point Est.

95% CI

   

Anti Spike IgG (BAU/ml)

0.57

(0.37, 0.87)

   

PsV-nAb ID50 (IU50/ml)

0.48

(0.27, 0.86)

   
  1. Analyses were adjusted for age and baseline risk score. Maximum failure event 92 days post Day 57 visit.
  2. *P-values are not shown for B because they are structurally identical to those for A.
  3. **Q-value and FWER (family-wise error rate) are computed over the two p-values for the two quantitative markers using the Westfall and Young permutation method (10,000 replicates).
Back to article page